A new low-dose pilocarpine agent can be administered up to twice a day for maximum duration of effect. It is hoped to result in fewer adverse effects than Vuity.
A panel agreed on many aspects of pre-op and intraoperative decision-making. They disagreed, however, when considering issues related to lens selection.
With one med available and others coming soon, patients have more options than ever for near vision correction. Do they offer enough to make a difference in a well-established market?